ORIGINAL PAPER

FASCIN OVEREXPRESSION IS ASSOCIATED WITH HIGHER GRADERS OF BREAST CANCER

Ata Abbasi¹, Farahnaz Noroozini¹, Samira Anvar¹, Mohammad Amin Abbasi², Sonia Hosseinzadeh¹, Seyed Arman Seyed Mokhtari³

¹Department of Pathology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
²Firoozabadi Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
³Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran

In the present study, we tried to evaluate the relationship between Fascin molecule expression and other histopathologic parameters, especially tumor grade and hormone profile. Sixty-one malignant breast tumors were enrolled in this study. Fascin marker staining was performed on paraffin blocks of breast samples using immunohistochemistry (IHC) method. The age range of patients was 26-87 years, with an average of 48.41 ± 1.68. Our results showed that fascin expression was significantly higher in tumors with high-grade histology, lymph node involvement and larger tumor size (p = 0.04, 0.04, 0.04, respectively). Also, fascin expression in triple-negative tumors was significantly higher than other molecular subtypes (p = 0.001). Fascin can be used as an important marker in evaluating breast cancer especially in triple-negative tumors.

Key words: breast cancer, fascin, immunohistochemistry, histopathologic, tumors, IHC.

Introduction

Breast cancer is the most common type of cancer and the second leading cause of cancer-related death among women [1]. Its incidence has increased over the last decade in the Asian countries [2, 3]. Breast cancer is the most common cancer among Iranian women and more than 30 percent of patients are less than 30 years old [4]. Considering its high frequency and increasing incidence rate, there has been an ongoing effort to find new methods for patients' treatment but considering remarkable improvements, significant mortality and morbidity still exist [5].

Fascin is a 55-kDa actin-bundling protein which is normally expressed in neuronal, mesenchymal, and endothelial cells, and is low or absent in normal epithelial cells [6, 7]. Recent studies have reported overexpression of fascin in several types of malignancies, including lung [8], colon [9], stomach [10], ovary [11] and breast [12]. Previous studies on breast cancer have shown that fascin expression was associated with poor prognosis and some studies have suggested to use fascin as a potential therapeutic target especially in triple-negative tumors [13, 14, 15]. In this study, we tried to evaluate the expression of fascin in human breast cancer using immunohistochemistry (IHC) method and explore its correlation with clinicopathological findings.

Material and methods

In this study, 61 paraffin-embedded samples of breast cancer collected by pathology department of Urmia University of Medical Sciences, Urmia, Iran were enrolled. All embedded paraffin blocks were
sectioned at 4 micrometer and sections were stained by hematoxylin and eosin (HE) method for routine histologic examination and tumor grading. Tumor grading was performed according to Nottingham modification of Bloom-Richardson system.

IHC staining

For IHC staining 5 consecutive sections were obtained and stained for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER 2/neu), ki67 and Fascin according to manufacturer’s guidelines.

All antibodies and associated reagents were obtained from DAKO Corporation, Glostrup, Denmark. We also used Hodgkin lymphoma and Reed-Sternberg cells as positive control for Fascin and stained in each staining run. Histologic evaluation was performed using a light microscope (Olympus CX41, Japan).

ER and PR IHC reporting

The immunohistochemistry results for ER, PR and Her2/neu were interpreted according to the College of American Pathologists (CAP) protocols as following: For ER and PR staining, nuclear positivity was scored 0 to 5 as following: 0 (0%), 1 (< 1%), 2 (1-10%), 3 (11-33%), 4 (34-66%), and 5 (> 67%).

The intensity of staining (IS) was graded as 0, 1, 2 and 3 when there was none, mild, moderate or strong staining, respectively. Finally Allred score was calculated by summing up the values for proportion and intensity of staining. The Allred score range was between 0-8 and the results higher than 2 was considered as positive [16].

Her2/neu IHC reporting

Her2/neu staining results were reported as following: 0 (negative) if there was no immunoreactivity, 1+ (negative) faint or weak incomplete membranous immunoreactivity in > 10% of tumor cells, 2+ (equivocal) weak to moderate complete membrane immunoreactivity in > 10% of tumor cells or circumferential (complete) intense membranous staining < 10% of cells and 3+ (positive) more than 10% of the tumoral cells showed circumferential (complete) intense and uniform membranous staining with homogenous chicken-wire pattern [16].

Ki67 IHC reporting

Percent of positive cells (nuclear staining) in hot spot areas were reported as ki67 index. The cases were divided into two groups: index ≤ 14% and more than 14%.

Molecular subtyping

Samples were also classified on molecular subtypes according to the following:

Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 positive (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative) [17].

Fascin IHC reporting

Cytoplasmic staining pattern was considered as positive result. Reed Sternberg cells in a Hodgkin lymphoma were used as positive control in every staining run.

Statistical analysis

The results are expressed as mean ±SD. Statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Normality of data was evaluated with the Kolmogorov-Smirnov test. The statistical differences between proportions were determined by χ² analysis. Numerical data were evaluated using analysis of variance, followed by Tukey’s post hoc test. P < 0.05 was considered as significant.

Results

Patients’ mean age was 48.4 ± 1.56 years. Twenty five (41%) masses were on the right and 36 (59%) were on the left breast. Two (3.3%) of the evaluated tumors were grade I, 33 (54.5%) were grade II, and 26 (42.2%) were grade III.

ER, PR and Her2/neu staining

Of 61 cases, 22 (36.1%) were luminal A, 12 (19.7%) were Her2 positive, 19 (31.1%) were luminal B, and 8 (13.1%) Were triple negative (Basal-like). Patients’ demographic data and tumor characteristics are mentioned in Table I in details.

Fascin staining

IHC staining for Fascin marker revealed that 16 cases (26.2%) were positive and 45 cases (73.8%) were negative for this marker (Fig. 1). There was a statistical significant relationship between fascin expression and histological grade of tumor, tumor size, axillary lymph node involvement and molecular subtype (p = 0.04, p = 0.03, p = 0.04 and p = 0.0001, respectively). Moreover, there was an inverse correlation between fascin expression and both estrogen receptor (p = 0.005) and progesterone receptor (p = 0.0001) expressions. However no correlation was found between fascin expression and tumor...
### Table I. Tumor characteristics and Fascin expression in examined breast cancer cancers

|                          | N (%) | Fascin Expression |   |          |   |          |   |          |
|--------------------------|-------|-------------------|---|----------|---|----------|---|----------|
|                          |       | Negative (n = 45) |   | Positive (n = 16) | P value |
| **Histological type**    |       |                   |---|------------|---|--------|
| Invasive ductal carcinoma| 55 (90.2) | 40 | 15 | 0.099 |
| Invasive lobular carcinoma| 5 (8.2) | 5 | 0 |  |
| Medullary carcinoma      | 1 (1.6) | 0 | 1 |  |
| **Histologic grade**     |       |                   |---|------------|---|--------|
| Grade I                  | 2 (3.3) | 2 | 0 | < 0.05 |
| Grade II                 | 33 (54.5) | 28 | 5 |  |
| Grade III                | 26 (42.2) | 15 | 11 |  |
| **Tumor Side**           |       |                   |---|------------|---|--------|
| Right                    | 25 (40.9) | 18 | 7 | 0.51 |
| Left                     | 36 (59.1) | 27 | 9 |  |
| **Tumor Size**           |       |                   |---|------------|---|--------|
| < 2 cm                   | 3 (4.9) | 1 | 2 | < 0.05 |
| 2-5 cm                   | 44 (72.1) | 36 | 8 |  |
| > 5cm                    | 14 (22) | 8 | 6 |  |
| **Lymph-vascular invasion** |   |                   |---|------------|---|--------|
| Present                  | 43 (70.5) | 33 | 10 | 0.376 |
| Not identified           | 18 (29.5) | 12 | 6 |  |
| **Perineural invasion**  |       |                   |---|------------|---|--------|
| Present                  | 19 (31.1) | 13 | 6 | 0.367 |
| Not identified           | 42 (68.9) | 32 | 10 |  |
| **Nipple involvement**   |       |                   |---|------------|---|--------|
| Present                  | 12 (18.6) | 10 | 2 | 0.496 |
| Not identified           | 49 (81.4) | 35 | 14 |  |
| **Skin involvement**     |       |                   |---|------------|---|--------|
| Present                  | 13 (20.3) | 10 | 5 | 0.642 |
| Not identified           | 48 (79.7) | 35 | 13 |  |
| **Axillary lymph node Involvement** |   |                   |---|------------|---|--------|
| Present                  | 49 (81.4) | 38 | 11 | < 0.05 |
| Not identified           | 12 (18.6) | 7 | 5 |  |
| **Estrogen receptor**    |       |                   |---|------------|---|--------|
| Positive                 | 35 (57.4) | 31 | 4 | 0.003 |
| Negative                 | 26 (42.6) | 14 | 12 |  |
| **Progestosterone Receptor** |     |                   |---|------------|---|--------|
| Positive                 | 36 (59) | 35 | 1 | 0.0001 |
| Negative                 | 25 (41) | 10 | 15 |  |
| **HER 2**                |       |                   |---|------------|---|--------|
| Positive                 | 12 (19.7) | 6 | 6 | 0.345 |
| Negative                 | 49 (80.3) | 38 | 11 |  |
Fascin overexpression in breast cancer

histological subtype, tumor side, Lymph-vascular invasion, perineural invasion, nipple involvement, skin involvement, HER 2/neu and Ki 67 status. The relationship between fascin expression and clinicopathological parameters is shown in Table I.

Discussion

Breast cancer is the most common malignant tumour as well as the most common cause of death by carcinomas in the female population [1]. The incidence of breast carcinoma is lower in Iran compared to most other countries. However an increased incidence has been recorded making it the most prevalent carcinoma in our country [18, 19]. Additionally, an estimated 30% of the affected population in our country are younger than 40 years old comparing to Western countries in which below 6% of patients are younger than 40 [18].

Currently, the mainstay of diagnosis of neoplastic diseases is the employment of biomarkers. Although many prognostic factors such as clinical staging, invasion of the lymphatic system, histological grading and oestrogen and progesterone receptor presentation are available for breast cancer, the use of specific markers yields more information regarding the evaluation of disease course and treatment of choice. One of the major prognostic determinants in breast carcinoma is invasion and metastasis which is the result of multiple processes which could enable the malignant cells to possess high motility and overcome the intercellular and cell to matrix adhesion [20]. The increased motility is the result of cytoskeletal microfilament rearrangement and actin cross-linking [20, 21]. Fascin, a 55 kDa protein regulates the rearrangement of cytoskeletal components and plays an important role in adjusting actin-based structures. Immunohistochemical analyses have revealed that the expression of fascin was related to clinical progression and invasion of the tumour, and decreased short term survival [8].

The present study showed a significant relationship between fascin expression with tumours of high histologic grading, axillary lymph node metastasis and a larger tumour size. In addition, we also observed higher expression of fascin molecule in triple negative tumours.

In a study performed by Chao-Qung Wang and et al on 457 breast cancer patients in China, they found that the expression of fascin is significantly elevated in triple negative tumours compared to Luminal A and B and HER2 enriched subtypes of breast cancer (p < 0.01), [22].

In another study performed by Hiromichi et al., on 301 cases of invasive ductal carcinoma, they also revealed that the expression of fascin in triple negative breast cancers was significantly higher than other tumour subtypes (p = 0.0056). Our results were in line with these mentioned studies showing that Fascin molecule expression is increased in triple negative cases. Although in contrast to our study, they have found no meaningful relationship between

| Molecular Subtype | Fascin Expression | p value |
|-------------------|------------------|---------|
|                   | Negative (n = 45)| Positive (n = 16) |     |
| Luminal A         | 22 (36.1)        | 21       | 1     | 0.0001 |
| Luminal B         | 19 (31.1)        | 17       | 2     |
| HER-2/neu         | 12 (19.7)        | 6        | 6     |
| Triple negative   | 8 (13.1)         | 1        | 7     |
| Ki 67             |                  |          |       |
| Ki67 ≤ 14 %       | 22 (36.1)        | 11       | 1     | 0.115  |
| Ki67 >14%         | 39 (63.9)        | 14       | 7     |
the expression of fascin molecule and tumour size or lymphatic invasion [23].

In a study performed by Nermeen Salah Yussef and et al., they have discovered that expression of fascin was related to lymph node metastasis (p = 0.001), higher tumour stage (p = 0.004) and negative expression of ER (p = 0.002) and PR (p = 0.003) [24].

Similar to our findings, Monther Al-Alwan and et al. have reported a strong relationship between the expression of fascin and basal-like breast cancer (p < 0.001), negative expression of ER (p < 0.001) and PR (p < 0.020), larger tumour size (p = 0.091) and distant metastasis (p = 0.017) [25]. Some other studies have also reported higher expression of Fascin in triple negative or high grade tumours [13, 14, 26].

Conclusions

In conclusion, based on the present findings it could be suggested that the expression of fascin is related to higher histologic grading of breast cancer, lymph node metastasis, tumour size, and triple negative breast cancer subtype. This marker is able to provide valuable information as well as being a prognostic factor, on cancer grading system based on AJCC criteria [27]. This marker may also be useful in the treatment of breast cancers, especially in those with triple negative subtypes which are less responsive to hormonal treatments.

Authors declare no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
2. Ghoneim M, Momenmovalmed Z, Salehiyeh H. Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev 2016; 17: 47-52.
3. DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
4. Zahmatkesh B, Keramat A, Alavi N, et al. Breast cancer trend in Iran from 2000 to 2009 and prediction till 2020 using a trend analysis method. Asian Pac J Cancer Prev 2016; 17: 1493-1498.
5. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67: 439-448.
6. Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol 2010; 42: 1614-1617.
7. Yamashiro S, Matsumura F. Fascin. Encyclopedia of Signaling Molecules 2016; 1-7.
8. Zhao J, Zhou Y, Zhang Z, et al. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett 2010; 290: 258-247.
9. Pakor BM, Przybyzycz A, Lubowicka E, et al. Immunohistochemical expression of Fascin-1 in colorectal cancer in relation to clinical and pathological parameters. Folia Histochem Cyto 2018; 1: 106-112.
10. Zheng HC, Zhao S. The meta and bioinformatics analysis of fascin expression in gastric cancer: a potential marker for aggressiveness and worse prognosis. Oncotarget 2017; 8: 105574.
11. Park SH, Song JY, Kim YK, et al. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol 2014; 44: 637-646.
12. Lee HJ, An HJ, Kim TH, et al. Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients. J Cancer 2017; 8: 3122-3129.
13. Min KW, Chae SW, Kim DH, et al. Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett 2015; 10: 121-130.
14. Erdoğan G, Peytereli HE, Çolak T, et al. Fascin expression in invasive ductal carcinoma of breast. Turk J Pathol 2010; 26: 130-135.
15. Esnakula AK, Ricks-Santi L, Kwagyan J, et al., Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol 2014; 67: 153-160.
16. Isqal BM, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Medical Journal of DR. DY Patil University 2016; 9: 674.
17. Kondov B, Milenkovich Z, Kondov G, et al. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. Open Access Maced J Med Sci 2018; 6: 961-967.
18. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
19. Ghoneim M, Pournamdar Z, Salehiyeh H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016; 17 (83): 43-46.
20. Duncan MW, et al. Biomarkers for Diagnosis of Breast Cancer 2011, Google Patents.
21. Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-298.
22. Wang CQ, Tang CH, Chang HT, et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med 2016; 5: 1983-1988.
23. Tsuchiya H, Sasaki A, Tsunoda Y, et al. Fascin is Expressed in Basal-Like Type Triple Negative Breast Cancer Associated with High Malignant Potential in Japanese Women. Int J Cancer Clin Res 2015; 2: 035.
24. Youssef NS, Hakim SA. Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol 2014; 9: 136.
25. Al-Alwan M, Olabi S, Ghebeh H, et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PloS One 2011; 6: e27339.
26. Grothey A, Hashizume R, Sahin AA, et al. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000; 83: 870-873.
27. Kuresny S, Sapountzi V, Prag S, et al. Fascins, and their roles in cell structure and function. Bioessays 2002; 24: 350-361.

Address for correspondence

Seyed Arman Seyed Mokhtari
Student Research Committee
Urmia University of Medical Sciences
Urmia, Iran
tel. +98-939-905-3874
e-mail: armanmxt@yahoo.com, aabbasi@alumnus.tums.ac.ir